• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by NovaBay Pharmaceuticals Inc.

    11/25/25 5:26:44 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBY alert in real time by email
    S-8 1 nby20251125_s8.htm FORM S-8 nby20251125_s8.htm

     

    As filed with the Securities and Exchange Commission on November 25, 2025.

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    NovaBay Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    68-0454536

    (State or other jurisdiction of incorporation or organization)

    (I.R.S. Employer Identification No.)

     

    2000 Powell Street, Suite 1150, Emeryville, CA 94608
    (510) 899-8800
    (Address, including zip code, of Principal Executive Offices)

     

    2017 Omnibus Incentive Plan
    (Full title of the plan)

     

    Michael Kazley
    Chief Executive Officer
    2000 Powell Street, Suite 1150
    Emeryville, CA 94608
    (510) 899-8838
    (Name, address, and telephone number, including area code, of agent for service)

     

    Copies to:
    Rachel Phillips

    Ropes & Gray LLP
    1211 Avenue of the Americas

    New York, NY 10036

    (212) 596-9000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 registers a total of 1,195,428 shares of common stock, par value $0.01 per share (the “Common Stock”), of NovaBay Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for issuance under the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (the “Plan”).

     

    The number of shares of Common Stock available for issuance under the stockholder-approved Plan is subject to an automatic annual increase on the first day of each of the Company’s fiscal years beginning on January 1, 2018 and ending on January 1, 2027 by an amount equal to (i) four percent (4%) of the number of shares of Common Stock outstanding on the last day of the immediately preceding fiscal year or (ii) such lesser number of shares of Common Stock as determined by the Board of Directors (the “Board”). For 2025, the Board authorized an increase of 195,428 shares of Common Stock under the Plan effective January 1, 2025, representing four percent (4%) of the 4,885,693 shares of Common Stock issued and outstanding as of December 31, 2024. In addition, on October 16, 2025, the Company’s stockholders approved an increase of 1,000,000 shares available for issuance under the Plan pursuant to a stockholder vote at the Company’s 2025 stockholder meeting. These shares are in addition to the 1,892 shares of Common Stock registered on the Company’s Form S-8 filed on June 2, 2017 (File No. 333-218469), the 17,582 shares of Common Stock registered on the Company’s Form S-8 filed on January 19, 2018 (File No. 333-222625) pursuant to the annual increase in 2018 according to the Plan’s evergreen provision, the 1,470 shares of Common Stock registered on the Company’s Form S-8 filed on February 7, 2020 (File No. 333-236328) pursuant to the annual increases in 2019 and 2020 according to the Plan’s evergreen provision (with 558 shares of Common Stock from the 2019 annual increase and 912 shares of Common Stock from the 2020 annual increase), the 1,364 shares of Common Stock registered on the Company’s Form S-8 filed on January 15, 2021 (File No. 333-252155) pursuant to the annual increase in 2021 according to the Plan’s evergreen provision, the 1,559 shares of Common Stock registered on the Company’s Form S-8 filed on May 13, 2022 (File No. 333-264953) pursuant to the annual increase in 2022 according to the Plan’s evergreen provision, the 2,326 shares of Common Stock registered on the Company’s Form S-8 filed on March 31, 2023 (File No. 333-271053) pursuant to the annual increase in 2023 according to the Plan’s evergreen provision, and the 12,219 shares of Common Stock registered on the Company’s Form S-8 filed on June 21, 2024 (File No. 333-280388) pursuant to the annual increase in 2024 according to the Plan’s evergreen provision.

     

    Since the Plan provides that the annual increase in the aggregate number of shares that may be issued pursuant to the Plan’s evergreen provision begins for fiscal years commencing January 1, 2018, this Registration Statement accounts for the seventh share increase under the evergreen provision. The number of shares of Common Stock registered under each prior Registration Statement listed above has been adjusted to account for all previous stock splits.

     

    The contents of the prior Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on June 2, 2017, January 19, 2018, February 7, 2020, January 15, 2021, May 13, 2022, March 31, 2023 and June 21, 2024 (File Nos. 333-218469, 333-222625, 333-236328, 333-252155, 333-264953, 333-271053 and 333-280388 respectively), are incorporated herein by reference and made part of this Registration Statement.

     

    This Registration Statement relates to securities of the same class as those to which the prior Registration Statements listed directly above relate, and is submitted in accordance with General Instruction E to Form S-8 regarding the Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

     

    The following documents filed by the Company with the Commission are incorporated by reference into this Registration Statement:

     

     

    1.

    The Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Commission on April 2, 2024;

     

     

    2.

    The Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, as filed with the Commission on May 15, 2025, June 30, 2025, as filed with the Commission on August 14, 2025, and September 30, 2025, as filed with the Commission on November 7, 2025;

     

     

    3.

    The Company’s Current Reports on Form 8-K filed with the Commission on January 10, 2025, January 22, 2025, January 23, 2025, February 4, 2025, March 7, 2025, March 11, 2025, April 22, 2025, August 19, 2025, August 26, 2025, October 9, 2025, October 20, 2025, October 21, 2025 and October 22, 2025; and

     

     

    4.

    The description of the Company’s Common Stock which is contained in the Company’s registration statement on Form 8-A, as filed with the Commission on August 29, 2007, as updated by the Company’s Current Report on Form 8-K filed with the Commission on June 29, 2011, and including any amendments or reports filed for the purposes of updating this description, including Exhibit 4.1 to the Company’s Annual Report for the year ended December 31, 2024.

     

    All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any such information so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

     

    Notwithstanding the foregoing, we are not incorporating by reference information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, nor any other document or information deemed to have been furnished and not filed in accordance with Commission rules.

     

    Item 4.

    Description of Securities.

     

    Not applicable.

     

    Item 5.

    Interests of Named Experts and Counsel.

     

    The validity of the issuance of the shares of Common Stock registered under this Registration Statement has been passed upon for the Company by Ropes & Gray LLP.

     

     

     

     

    Item 6.

    Indemnification of Directors and Officers.

     

    The Company’s amended and restated certificate of incorporation, as amended, provides that the liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. If the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Company shall be eliminated to the fullest extent permitted by the Delaware General Corporation Law, as so amended. Under the Delaware General Corporation Law, no director will be personally liable to the Company or the Company’s stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

     

     

    ●

    for any breach of the duty of loyalty to the Company or the Company’s stockholders;

     

     

    ●

    for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

     

     

    ●

    for unlawful payment of dividends or unlawful stock repurchases or redemptions under Section 174 of the Delaware General Corporation Law; and

     

     

    ●

    for any transaction from which the director derived an improper personal benefit.

     

    The Company’s amended and restated bylaws provide that:

     

     

    ●

    the Company is required to indemnify the Company’s directors and executive officers to the fullest extent not prohibited by Delaware law, subject to limited exceptions;

     

     

    ●

    the Company may indemnify the Company’s other employees and agents as set forth in the Delaware General Corporation Law;

     

     

    ●

    the Company is required to advance expenses to the Company’s directors and executive officers as incurred in connection with legal proceedings against them for which they may be indemnified, against an undertaking by the indemnified party to repay such advances if it is ultimately determined that the indemnified party is not entitled to indemnification; and

     

     

    ●

    the rights conferred in the amended and restated bylaws are not exclusive.

     

    The information provided above is a summary of relevant provisions of our amended and restated certificate of incorporation, as amended, our amended and restated bylaws and certain provisions of the Delaware General Corporation Law. We urge you to read the full text of these documents, forms of which have been filed with the Commission, as well as the referenced provisions of the Delaware General Corporation Law because they are the legal documents and provisions that will govern matters of indemnification with respect to our directors and officers.

     

    The Company has entered into indemnification agreements with each of the Company’s directors and executive officers that require the Company to indemnify these persons against all direct and indirect costs of any type or nature whatsoever, including attorney’s fees, witness fees, and other out-of-pocket costs of whatever nature, incurred by the director or officer in any action or proceeding, whether actual, pending or threatened, subject to certain limitations, to which any of these people may be made a party by reason of the fact that he or she is or was a director or an executive officer of the Company or is or was serving or at any time serves at the request of the Company as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.

     

    The Company has purchased insurance on behalf of any person who is or was a director or officer of the Company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

     

    Item 7.

    Exemption from Registration Claimed.

     

    Not applicable.

     

     

     

     

    Item 8.

    Exhibits.

     

    Exhibit No.

     

    Description of Document

         

    3.1

     

    Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company’s Annual Report on Form 10-K, as filed with the Commission on March 21, 2018 (File No. 001-33678))

         

    3.2

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, as filed with the Commission on June 4, 2018 (File No. 001-33678))

         

    3.3

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, as filed with the Commission on May 28, 2020 (File No. 001-33678))

         

    3.4

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, as filed with the Commission on May 24, 2021 (File No. 001-33678))

         

    3.5

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, as filed with the Commission on February 1, 2022 (File No. 001-33678))

         

    3.6

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, as filed with the Commission on November 18, 2022 (File No. 001-33678))

         

    3.7

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, as filed with the Commission on May 31, 2024 (File No. 001-33678))

         

    3.8

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, as filed with the Commission on October 20, 2025 (File No. 001-33678))

         

    3.9

     

    Certificate of Designation for the Series B Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, as filed with the Commission on November 1, 2021 (File No. 001-33678))

         

    3.10

     

    Certificate of Designation for the Series C Preferred Stock (incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K, as filed with the Commission on November 18, 2022 (File No. 001-33678))

         

    3.11

     

    Certificate of Designation for the Series D Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, as filed with the Commission on August 19, 2025 (File No. 001-33678))

         

    3.12

     

    Certificate of Designation for the Series E Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, as filed with the Commission on October 22, 2025 (File No. 001-33678))

         

    3.13

     

    Amended and Restated Bylaws of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the Commission on June 14, 2023)

         

    4.1

     

    Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 3.10, 3.11, 3.12, and 3.13.

         

    4.2

      Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 of the Company’s Registration Statement on Form S-8, as filed with the Commission on June 2, 2017 (SEC File No. 280388))
         

    5.1*

     

    Opinion of Ropes & Gray LLP

         

    23.1*

     

    Consent of WithumSmith+Brown, PC

         

    23.2*

     

    Consent of Ropes & Gray LLP (included in Exhibit 5.1)

         

    24.1*

     

    Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)

         

    99.1

     

    NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 (File No. 333-218469), as filed with the Commission on June 2, 2017)

         

    99.2

     

    Forms of agreements for use under the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.2 to the Company’s Registration Statement on Form S-8 (File No. 333-218469), as filed with the Commission on June 2, 2017)

         

    107*

     

    Filing Fee Table

     

     

    * Exhibits marked with an asterisk (*) are filed herewith.

     

     

     

     

    Item 9.

    Undertakings.

     

    Incorporated by reference to Item 9 in the Company’s Registration Statement on Form S-8, filed with the Commission on June 2, 2017.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California on November 25, 2025.

     

     

    NOVABAY PHARMACEUTICALS, INC.

         
         
       

    /s/ Michael Kazley

       

    Michael Kazley

       

    Chief Executive Officer

     

    KNOW ALL PERSONS BY THESE PRESENTS that each of the undersigned officers and directors does hereby constitute and appoint Michael Kazley or his substitute or substitutes, as his or her true and lawful attorney-in-fact and agent, with full power and authority to do any and all acts and things and to execute and file or cause to be filed any and all instruments, documents or exhibits which said attorney and agent determines may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement and to any and all instruments, documents or exhibits filed as part of, or in conjunction with, this Registration Statement or amendments or supplements thereof, with the powers of substitution and revocation, and each of the undersigned hereby ratifies and confirms all that said attorney and agent, or his substitute or substitutes, shall lawfully do or cause to be done by virtue hereof. In witness whereof, each of the undersigned has executed this Power of Attorney as of the dates indicated below.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. This document may be executed by the signatories hereto on any number of counterparts, all of which shall constitute one and the same instrument.

     

    Signature

     

    Title

     

    Date

             

    /s/ Michael Kazley

     

    Chief Executive Officer and Chairman

     

    November 25, 2025

    Michael Kazley

     

    (principal executive officer)

       
             

    /s/ Tommy Law

     

    Chief Financial Officer

     

    November 25, 2025

    Tommy Law

     

    (principal financial and accounting officer)

       
             

    /s/ Paul E. Freiman

     

    Director

     

    November 25, 2025

    Paul E. Freiman, Ph.D

           
             

    /s/ Swan Sit

     

    Director

     

    November 25, 2025

    Swan Sit

           
             

    /s/ Yenyou (Jeff) Zheng

     

    Director

     

    November 25, 2025

    Yenyou (Jeff) Zheng, Ph.D

           
             

     

     
    Get the next $NBY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards

    EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's continued listing standards. As previously disclosed, the NYSE American notified the Company on April 18, 2024 and May 28, 2024 that it was not in compliance with the continued listing standards of the NYSE American Company Guide. Specifically, the notifications indicated that the Company was not in compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company guide, requiring a listed company to have stockholders' equity of at least $6 million. Following the issuance and sale of p

    10/20/25 7:07:28 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

    EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common stock, NYSE American advised the Company that its common stock will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of tradi

    9/18/25 4:30:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

    EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because

    8/26/25 4:05:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Poplar Point Capital Partners Lp bought $15,967 worth of shares (28,731 units at $0.56) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:50:08 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $74,519 worth of shares (123,365 units at $0.60) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:46:27 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $30,718 worth of shares (49,927 units at $0.62) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:40:59 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Framework Ventures Iv L.P. converted options into 56,806,080 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    11/3/25 9:39:23 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner R01 Fund Lp converted options into 56,806,080 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    11/3/25 9:38:56 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kazley Michael John converted options into 56,806,080 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    11/3/25 9:38:31 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    SEC Filings

    View All

    SEC Form EFFECT filed by NovaBay Pharmaceuticals Inc.

    EFFECT - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    11/28/25 12:15:10 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by NovaBay Pharmaceuticals Inc.

    S-8 - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    11/25/25 5:26:44 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-3/A filed by NovaBay Pharmaceuticals Inc.

    S-3/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    11/25/25 5:24:49 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Leadership Updates

    Live Leadership Updates

    View All

    NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

    EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common stock, NYSE American advised the Company that its common stock will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of tradi

    9/18/25 4:30:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innovations in Disinfection Technology Aid the Return of Workers

    NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi

    12/9/20 9:00:00 AM ET
    $NBY
    $CEMI
    $BSGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $NBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc.

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    11/8/24 5:31:40 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    2/14/24 2:52:33 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    2/13/24 5:17:39 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Financials

    Live finance-specific insights

    View All

    NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

    EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because

    8/26/25 4:05:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

    EMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the Company's non-voting convertible preferred stock. NovaBay has received $3.85 million in the first of two closings under the agreement. Effective immediately, Mr. Lazar has been appointed NovaBay's Chief Executive Officer and a director of the Company. Former Chief Executive Officer Justin Hall has assumed the newly created position of Vice President of Business Development. At NovaBay's Special Meeting on April 16, 2025, stockholders

    8/19/25 5:25:32 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and

    8/1/24 6:50:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care